Andrew M Haidle

This inventor holds 25 USPTO granted patents and 7 published patent applications, plus 3 CIPO patents and 17 EPO patents, primarily in Spleen Tyrosine Kinase Inhibitors. Top assignees: Merck Sharp + Dohme Corp., Merck Canada Inc., Merck + Co., Inc.. Active years: 2010-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Andrew M Haidle. Retrieved from https://idiyas.com/inventor/andrew-m-haidle

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 25 (Patent Applications = 7)

% Patents Active = 96.0

CIPO Patents = 3 (Patent Applications = 1)

EPO Patents = 17 (Patent Applications = 19)

Average Co-Inventor Count = 10.8

ph-index = 8

Forward Citations = 127(Granted Patents)

Location History:

Cambridge, MA (US) (2010 - 2017)
Somerville, MA (US) (2019 - 2023)

Company Filing History:

25 out of 2,405

Merck Sharp + Dohme Corp.

where one patent can have more than one assignee

Years Active: 2010-2025

Loading Chart...

Areas of Expertise:

IL4I1 Inhibitors

Aza-benzothiophene Compounds

STING Agonists

Cyclic Di-nucleotide Compounds

Thiazole-substituted Aminopyridines

Triazolyl Derivatives

Spleen Tyrosine Kinase

Janus Kinase Inhibitors

Imidazolyl Analogs

Substituted Pyridines

Aminopyrimidines

Pyrazolyl Derivatives

25 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12454525 - IL4I1 inhibitors and methods of use (2025-10-28),

2. 11702430 - Aza-benzothiophene compounds as STING agonists (2023-07-18),

3. 10793557 - Sting agonist compounds (2020-10-06),

4. 10766919 - Cyclic di-nucleotide compounds as sting agonists (2020-09-08),

5. 10738074 - Cyclic di-nucleotide compounds as STING agonists (2020-08-11),

6. 10730849 - Benzo[b]thiophene compounds as STING agonists (2020-08-04),

7. 10703738 - Benzo[b]thiophene compounds as STING agonists (2020-07-07),

8. 10414747 - Benzo[b]thiophene compounds as sting agonists (2019-09-17),

9. 9598405 - Thiazole-substituted aminopyridines as spleen tyrosine kinase inhibitors (2017-03-21),

10. 9586931 - Triazolyl derivatives as Syk inhibitors (2017-03-07),

11. 9487504 - Imidazolyl analogs as syk inhibitors (2016-11-08),

12. 9416111 - Substituted diazine and triazine spleen tyrosine kinease (Syk) inhibitors (2016-08-16),

13. 9376418 - Substituted pyridine spleen tyrosine kinase (SYK) inhibitors (2016-06-28),

14. 9353066 - Substituted phenyl-Spleen Tyrosine Kinase (Syk) inhibitors (2016-05-31),

15. 9290490 - Aminopyrimidines as Syk inhibitors (2016-03-22),

Title: Innovations in Immunotherapy: The Contributions of Andrew M. Haidle

Introduction

Andrew M. Haidle, based in Cambridge, MA, is a renowned inventor and researcher specializing in innovative therapeutic compounds. With an impressive portfolio of 24 patents, Haidle's work primarily focuses on the development of STING agonists that play a crucial role in inducing immune responses, particularly in cancer treatment.

Latest Patents

Haidle's latest patents include groundbreaking innovations such as Aza-benzothiophene compounds used as STING agonists. These compounds, defined by a specific general formula, demonstrate potential as inducers of type I interferon production, effectively acting as STING active agents. The patents highlight various processes for synthesizing these compounds and their applications in treating cell proliferation disorders, including cancer, through the inducement of immune responses.

Another significant patent involves a broad range of STING agonist compounds, further expanding the scope of potential therapeutic applications. These compounds are detailed within several general formulas and encompass various pharmaceutically acceptable salts, emphasizing their versatility in inducing STING-dependent type I interferon production.

Career Highlights

Haidle's career features key roles in prestigious organizations such as Merck Sharp & Dohme Corporation and Merck Canada Inc., where he has contributed significantly to pharmaceutical advancements. His work not only showcases his expertise in medicinal chemistry but also underscores his commitment to innovation in the medical field.

Collaborations

Throughout his career, Andrew M. Haidle has collaborated with notable colleagues, including Michael D. Altman and Alan B. Northrup. These partnerships have fostered an environment of shared knowledge and innovation, further enhancing the impact of his research in immunotherapy and beyond.

Conclusion

Andrew M. Haidle's contributions to the field of immunotherapy and his extensive patent portfolio reflect a commitment to advancing medical research for the benefit of patients. His innovative work in developing STING agonist compounds is poised to make a significant impact on the treatment of cancer and other cell proliferation disorders, highlighting the importance of continued research and development in this critical area of health.

Profile summary based on public USPTO records.